Who Supplies Ramipril to India from BULGARIA

To import finished pharmaceutical formulations containing Ramipril into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting Form 41 for registration and Form 10 for the import license. The manufacturer must also provide a valid manufacturing or wholesale license from their country of origin. The registration certificate is valid for three years and can be renewed by applying nine months before its expiry. The import license is also valid for three years and is renewable under similar conditions. The application process typically takes several months, depending on the completeness of the submitted documentation and the CDSCO's processing times.

Imported finished pharmaceutical formulations containing Ramipril must undergo quality testing at a CDSCO-approved laboratory in India. The manufacturer is required to submit samples from each batch for testing, along with the Certificate of Analysis (CoA) from the exporting country's laboratory. The CoA should include details such as method of analysis, impurity standards, and reference standards. Stability data, particularly for ICH Zone IV conditions, should also be provided. The testing process ensures that the imported formulations meet the standards set by the Indian Pharmacopoeia. Port inspection by customs drug inspectors is conducted to verify compliance with regulatory requirements.

In April 2025, the CDSCO introduced new regulations requiring import registration and licenses for all imported drugs, including finished formulations containing Ramipril. This measure aims to prevent the sale of unapproved or illegal medicines in the Indian market. The regulations stipulate that drugs manufactured in Special Economic Zones (SEZs) for export purposes are not permitted for transfer to the Domestic Tariff Area (DTA) for sale and distribution. Additionally, for unapproved and approved new drugs manufactured in SEZs, the requirements specified for manufacturing of new drugs under NDCT Rules 2019 and Drug Rules 1945 must be complied with.

India imports finished Ramipril formulations to meet the demand for antihypertensive treatments, particularly for patented or branded formulations and specific dosage forms not produced domestically. The domestic pharmaceutical industry may lack the capacity to manufacture certain specialized Ramipril formulations, leading to reliance on imports. The market size for Ramipril formulations in India is substantial, with a growing patient population requiring effective hypertension management.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations containing Ramipril under HS Code 30049071 is 10%. In addition to BCD, the Social Welfare Surcharge (SWS) is levied at 10% of the BCD, and the Integrated Goods and Services Tax (IGST) is applicable at 12%. There are no anti-dumping duties or exemptions for this product category. The total landed duty percentage is calculated by summing the BCD, SWS, and IGST.

India sources finished Ramipril formulations from Bulgaria due to the competitive advantages offered by Bulgarian manufacturers, such as patents, specialized dosage forms, and adherence to quality standards. Bulgaria's share in the Indian market for Ramipril formulations is notable, with the top supplier being BALKANPHARMA-DUPNITSA AD. Other suppliers include countries like China, Germany, and the United States, but Bulgaria's unique advantages make it a preferred source for certain formulations.

India imports finished Ramipril formulations from Bulgaria due to the availability of patented formulations, specialized dosage forms, and technology-licensed products that are not manufactured domestically. Bulgaria's adherence to international quality standards and competitive pricing further make it an attractive sourcing destination for Indian pharmaceutical companies.

Compared to other origins like China, Germany, and the United States, Bulgaria offers competitive pricing, high-quality products, and reliable delivery schedules. While China may offer lower prices, concerns about quality and regulatory compliance can be a drawback. Germany and the United States provide high-quality products but at higher prices. Bulgaria's unique advantage lies in its balance of quality and cost-effectiveness, making it a preferred choice for certain Ramipril formulations.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish strong relationships with suppliers. Monitoring regulatory developments in both India and Bulgaria is crucial to anticipate and adapt to any changes that may impact the supply chain.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stocks to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align order sizes with demand forecasts to optimize inventory costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure suppliers meet quality and regulatory standards.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Form 41: Apply for the Import Registration Certificate.